Learn about the Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

Recent financial performance 111

Growth strategies 112

Shifting focus from drug delivery to become a specialty pharma

company 113

Deals and alliances 113

SWOT analysis 114

Strengths 114

Weaknesses 115

Opportunities 115

Threats 116

Aradigm 118

Key technologies 118

AERx pulmonary drug delivery system 118

Liposomal Formulations 119

Therapeutic focus 119

Product portfolio and pipeline candidates 119

Recent financial performance 120

Growth strategies 122

Deals and alliances 122

SWOT analysis 123

Strengths 123

Weaknesses 123

Opportunities 124

Threats 124

3M 125

Key technologies 125

Pulmonary drug delivery technology 125

Transdermal drug delivery technology 126

Therapeutic focus 126

Product portfolio and pipeline candidates 127

Growth strategies 127

Deals and alliances 128

Chapter 5 Transdermal drug delivery system 132

Summary 132

Synopsis 133

Transdermal drug delivery technologies 133

Passive formulations 134

Active formulations 134

Therapeutic focus 135

Dynamics of the transdermal drug delivery market 135

Antares 137

Key technologies 137

Advanced transdermal delivery 137

Injection devices 138

Easy Tec fast melt oral disintegrating tablets 139

Therapeutic focus 139

Product portfolio and pipeline candidates 139

Recent financial performance 140

Growth strategies 142

Deals and alliances 143

SWOT analysis 145

Strengths 145

Weaknesses 146

Opportunities 147

Threats 148

Noven 150

Key technologies 150

DOT Matrix technology 150

Therapeutic focus 151

Product portfolio and pipeline candidates 152

Recent financial performance 153

Growth strategies 154

Deals and alliances 155

SWOT analysis 155

Strengths 155

Weaknesses 157

Opportunities 158

Threats 158

Alza 159

Key technologies 159

D-Trans 159

E-Trans 160

Macroflux 160

Stealth 160

Alzamer 161

Oros 161

Therapeutic focus 162

Product portfolio and pipeline candidate 162

Deals and alliances 163

SWOT analysis 164

Strengths 164

Weaknesses 165

Opportunities 166

Threats 166

Chapter 6 Conclusion 168

Financials 168

Growth strategies 169

Outlook 172

Glossary 174

Index 175

List of Figures

Figure 1.1: Drug delivery technologies are revenue boosters for pharma companies 22

Figure 1.2: Procardia XL patent expiry 23

Figure 1.3: Cardizem's reformulation strategy 25

Figure 1.4: Compliance, bioavailability and safety benefits via effectice drug delivery 27

Figure 1.5: Positioning of key drug delivery companies 29

Figure 1.6: Key drug delivery systems market share, 2006 31

Figure 2.7: Biovail financial performance, $m, 2003-2007 43

Figure 2.8: Biovail SWOT analysis 45

Figure 2.9: Elan financial performance, 2003-2007 ($m) 53

Figure 2.10: Elan SWOT analysis 56

Figure 2.11: SkyePharma financial performance, $m, 2003-2007 65

Figure 2.12: SkyePharma SWOT analysis 67

Figure 3.13: Alkermes financial performance, 2003-2007 80

Figure 3.14: Alkermes SWOT analysis 82

Figure 3.15: Bioject financial performance, 2003-2007 ($m) 89

Figure 3.16: Bioject SWOT analysis 91